TMCnet News
Compugen to Present Predictive Methodology for Discovery of Novel Immune Checkpoints at the Washington BioLeaders ForumTEL AVIV, Israel --(Business Wire)-- Compugen (News - Alert) Ltd. (NASDAQ: CGEN) today announced that Dr. John Hunter of Compugen USA, Inc. will present at the Washington BioLeaders Forum 2014 to be held next week in Washington, D.C. In his talk, which is scheduled for January 28 in the Phacilitate Immunotherapy Forum track, Dr. Hunter will demonstrate how Compugen has applied its predictive discovery platforms to identify novel immune checkpoints for targeted antibody immunotherapy in cancer. Validation data for reprsentative targets discovered by the Company will also be presented. Dr. Hunter is Site Head & Vice President, Antibody Research & Development at Compugen USA, Inc., a wholly owned subsidiary of Compugen Ltd. The Immunotherapy Forum 2014, which in previous years was held in Barcelona, is an annual international conference focusing on key emerging trends in novel immunotherapeutic modalities, including checkpoint inhibitors, adoptive T-cell therapies, other cancer vaccine technologies and oncolytic virus therapeutics. This is the first year that the forum is being held as part of the annual Washington BioLeaders Forum.
About Compugen
|